Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection

Eye

Volumn 23, Issue 12, 2009, Pages 2187-2193

  Artunay, O ^a   Yuzbasioglu, E ^a   Rasier, R ^a   Sengul A ^a   Bahcecioglu, H ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Endophthalmitis; Intravitreal injection

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; MOXIFLOXACIN; PREDNISOLONE ACETATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY; VITRECTOMY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ENDOPHTHALMITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINAL DEGENERATION; RETROSPECTIVE STUDIES;

EID: 68949120403     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.7     Document Type: Article

References (40)

1. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-339.
2. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
3. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
4. Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina 2007; 27(6): 662-680.
5. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-796.
6. Scott IU, Flynn Jr HW. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007; 27: 10-12.
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al., the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
8. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al., the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
9. Mason III JO, Albert Jr MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006; 26: 356-357.
10. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262-269.
11. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-261.
12. Jager RD, Aiello LP, Patel SC, Cunningham Jr ET. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24: 676-698.
13. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23(3): 240-242.
14. Aggio FB, Farah ME, De Melo GB, d'Azevedo PA, Pignatari AC, Höfling-Lima AL. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007; 21(3): 408-409.
15. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
16. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
17. Heier JS, Antosyk AN, PaVan PR, Leff SR, Rosenfeld PJ, Ciulla TA et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113: 642.
18. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145: 879-882.
19. Mason JO, Withe MF, Feist RM, Thomley ML, Albert MA, Persaud TO et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28: 564-567.
20. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98: 639-649.
21. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 113: 1479-1496.
22. Phillips WB, Tasman WS. Postoperative endophthalmitis in association with diabetes mellitus. Ophthalmology 1994; 101: 508-518.
23. Javitt JC, Street DA, Tielsch JM, Wang Q, Kolb MM, Schien O et al. National outcomes of cataract extraction; retinal detachment and endophthalmitis after outpatient cataract surgery. Ophthalmology 1994; 101: 100-105.
24. Eifrig CW, Flynn Jr HW, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers 2002; 33: 373-378.
25. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study [erratum in: Am J Ophthalmol 1996; 122: 920]. Am J Ophthalmol 1996; 122: 1-17. (Pubitemid 26230889)
26. Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Ophthalmol 2005; 123: 341-346.
27. Puliafito CA, Baker AS, Haaf J, Foster CS. Infectious endophthalmitis. Review of 36 cases. Ophthalmology 1982; 89: 921-929.
28. Shaarawy A, Meredith TA, Kincaid M, Dick J, Aguilar E, Ritchie DJ et al. Intraocular injection of ceftazidime. Effects of inflammation and surgery. Retina 1995; 15: 433-438.
29. Aguilar HE, Meredith TA, el-Massry A, Shaarawy A, Kincaid M, Dick J et al. Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Retina 1995; 15: 428-432.
30. Engelbert M, Mino De Kaspar H, Thiel M, Grasbon T, Ta CN, Schulze-Schwering M et al. Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis. Graefes Arch Clin Exp Ophthalmol 2004; 242: 313-320.
31. Kuhn F, Gini G. Ten years after. Are findings of the Endophthalmitis Vitrectomy Study still relevant today? Graefes Arch Clin Exp Ophthalmol 2005; 243: 1197-1199.
32. Doft BH, Kelsey SF, Wisniewski SR. Additional procedures after the initial vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy Study. Ophthalmology 1998; 105: 707-716.
33. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study [erratum in: Am J Ophthalmol 1996; 122: 920]. Am J Ophthalmol 1996; 122: 1-17. (Pubitemid 26230889)
34. Meredith TA, Trabelsi A, Miller MJ, Aguilar E, Wilson LA. Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci 1990; 31(1): 181-186. (Pubitemid 20042479)
35. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (0.5% moxifloxacin) is nontoxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthal 2005; 140: 497-504.
36. Haas MG, Yung C-W, Chaluvadi U, Davis TE. Vigamox: howgood is its self-preservation? J Cataract Refract Surg 2006; 32: 899-900.
37. Espiritu CRG, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007; 33: 63-68.
38. Gao H, Pennesi ME, Qiao X, Iyer MN,Wu SM, Holz ER et al. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci 2006; 47: 1606-1611.
39. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005; 123: 39-44.
40. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model. J Ocul Pharmacol Ther 2008; 24: 1-5.